(Q37954799)

25 August 2017

title

New and emerging agents for the treatment of castration-resistant prostate cancer (English)

1 reference

25 August 2017

1 reference

Celestia S Higano

1

1 reference

25 August 2017

E David Crawford

series ordinal

2

1 reference

25 August 2017

publication date

1 November 2011

1 reference

25 August 2017

1 reference

25 August 2017

volume

29

1 reference

25 August 2017

issue

6 Suppl

1 reference

25 August 2017

page(s)

S1-8

1 reference

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

25 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

STUDIES ON PROSTATIC CANCER

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Endocrine-Induced Regression of Cancers

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

American Society of Clinical Oncology recommendations for the initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Gonadotropin-releasing hormone: one polypeptide regulates secretion of luteinizing and follicle-stimulating hormones

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Tumor growth inhibition in patients with prostatic carcinoma treated with luteinizing hormone-releasing hormone agonists

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Castration-resistant prostate cancer: locking up the molecular escape routes

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Clinical states in prostate cancer: toward a dynamic model of disease progression

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Immunophenotypic characterization of 225 prostate adenocarcinomas with intermediate or high Gleason scores

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Sipuleucel-T immunotherapy for castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Placebo-controlled phase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Integrated data from 2 randomized, double-blind, placebo-controlled, phase 3 trials of active cellular immunotherapy with sipuleucel-T in advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Survival and PSA response of patients in the TAX 327 study who crossed over to receive docetaxel after mitoxantrone or vice versa

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Randomized, double-blind, controlled trial of mitoxantrone/prednisone and clodronate versus mitoxantrone/prednisone and placebo in patients with hormone-refractory prostate cancer and pain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Activity of second-line chemotherapy in docetaxel-refractory hormone-refractory prostate cancer patients : randomized phase 2 study of ixabepilone or mitoxantrone and prednisone.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

First- and second-line chemotherapy with docetaxel or mitoxantrone in patients with hormone-refractory prostate cancer: does sequence matter?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Prednisone plus cabazitaxel or mitoxantrone for metastatic castration-resistant prostate cancer progressing after docetaxel treatment: a randomised open-label trial

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Selective inhibition of CYP17 with abiraterone acetate is highly active in the treatment of castration-resistant prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Antitumor activity with CYP17 blockade indicates that castration-resistant prostate cancer frequently remains hormone driven.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Significant and sustained antitumor activity in post-docetaxel, castration-resistant prostate cancer with the CYP17 inhibitor abiraterone acetate

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Abiraterone and increased survival in metastatic prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: a randomized, double-blind study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

New therapies for castration-resistant prostate cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Development of a second-generation antiandrogen for treatment of advanced prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1-2 study

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

A pilot study of CTLA-4 blockade after cancer vaccine failure in patients with advanced malignancy

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Enhancement of antitumor immunity by CTLA-4 blockade

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Manipulation of T cell costimulatory and inhibitory signals for immunotherapy of prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Elimination of residual metastatic prostate cancer after surgery and adjunctive cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) blockade immunotherapy.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

A pilot trial of CTLA-4 blockade with human anti-CTLA-4 in patients with hormone-refractory prostate cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

Bone-targeted radium-223 in symptomatic, hormone-refractory prostate cancer: a randomised, multicentre, placebo-controlled phase II study.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2011.08.013

10.1016/J.UROLONC.2011.08.013

7 January 2021

Identifiers

DOI

1 reference

25 August 2017

1 reference